Startup
BioVersys, TASK, and GSK received €2.7 million from EDCTP for phase 2 of their clinical trials.
Read more
Success stories, testimonials from our investors, and startup news.
Don't miss out on the latest news from Satt Nord!
Read more
Read more
Read more
Read more
Read more
Read more